Sector |
|
Compare with Sector peers |
Industry |
|
Compare with Industry peers |
Website | http://www.lalchandanipathlab.com | |
Market Cap | 13.63 Cr. | |
Enterprise Value(EV) | 15.24 Cr. | 2022-03 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 2.15 | Trailing Twelve Months Ending 2022-03 |
Price-Earning Ratio (PE) | 14.60 | Trailing Twelve Months Ending 2022-03 |
Industry PE | 46.72 | Trailing Twelve Months Ending 2022-03 |
Book Value / Share | 23.90 | Trailing Twelve Months Ending 2022-03 |
Price to Book Value | 1.32 | Calculated using Price: 31.45 |
Dividend Yield | 0.00 | Period Ending 2022-03 |
No. of Shares Subscribed | 0.43 Cr. | 4,333,068 Shares |
FaceValue | 10 | |
Company Profile | ||
They are a provider of diagnostic and related healthcare tests and services in Delhi/NCR. Through their integrated network, they offer patients and healthcare providers a broad range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions. |
1 Day |
|
+4.83% |
1 Week |
|
+4.83% |
1 Month |
|
+14.36% |
3 Month |
|
-3.97% |
6 Month |
|
+32.14% |
1 Year |
|
-23.20% |
2 Year |
|
+121.48% |
5 Year |
|
|
10 Year |
|
5 years | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | |
Return on Equity (%) | 8.11 | 9.85 | 6.01 | 11.56 | 9.49 | |
Return on Capital Employed (%) | 10.06 | 12.57 | 9.17 | 14.88 | 13.07 | |
Return on Assets (%) | 4.23 | 6.53 | 4.30 | 7.46 | 5.60 |
Particulars | 5 years | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. |
Shh. Funds | 3 | 8 | 9 | 10 | 10 | |
Non Curr. Liab. | 1 | 1 | 2 | 3 | 3 | |
Curr. Liab. | 2 | 1 | 2 | 3 | 5 | |
Minority Int. | ||||||
Equity & Liab. | 6 | 10 | 12 | 15 | 18 | |
Non Curr. Assets | 2 | 4 | 4 | 6 | 7 | |
Curr. Assets | 4 | 6 | 8 | 9 | 11 | |
Misc. Exp. not W/O | 0 | 0 | 0 | 0 | 0 | |
Total Assets | 6 | 10 | 12 | 15 | 18 |
Particulars | 5 years | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. |
Net Sales | 3 | 5 | 6 | 10 | 11 | |
Other Income | 0 | 0 | ||||
Total Income | 3 | 5 | 6 | 10 | 11 | |
Total Expenditure | -2 | -4 | -5 | -8 | -9 | |
PBIDT | 1 | 1 | 1 | 2 | 2 | |
Interest | 0 | 0 | 0 | 0 | -1 | |
Depreciation | 0 | 0 | 0 | -1 | -1 | |
Taxation | 0 | 0 | 0 | 0 | 0 | |
Exceptional Items | ||||||
PAT | 0 | 1 | 0 | 1 | 1 | |
Adjusted EPS | 1 | 1 | 1 | 2 | 2 |
Particulars | 5 years | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. |
Cash Fr. Operatn. | 1 | 0 | 0 | 1 | 2 | |
Cash Fr. Inv. | -1 | -2 | -1 | -2 | -2 | |
Cash Fr. Finan. | 2 | 4 | 1 | 2 | 0 | |
Net Change | 1 | 1 | 0 | 1 | 1 | |
Cash & Cash Eqvt | 1 | 2 | 2 | 3 | 4 |
Tue, 29 Nov 2022
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 |
||||||||||||||
Wed, 23 Nov 2022
Statement Of Investor Complaints For The Quarter Ended September 2022
|
||||||||||||||
Mon, 14 Nov 2022
Board Meeting Outcome for Outcome Of Board Meeting We are hereby submitting the Unaudited Financial Results along with Limited Review Report for the half year ended on 30th September 2022.1. Un-audited Financial Results for the half year ended on 30th September 2022.2. Un-audited Statement of Assets and Liabilities for the half year ended on 30th September 2022.3. Cash Flow Statement for the half year ended on 30th September 2022.4. Limited Review Report for the half year ended 30th September 2022. |
Mon, 30 Jan 2023 |
|
|
|
|
|